RxDoctor Payments Data

Julia Lainhart, PA

Physician Assistant · Lincoln, NENPI 1487248506

Payments from drug & device makers

$936in general payments, 2019–2025

Across 40 payments — averaging $23.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$235
  • Alkermes, Inc.$177
  • AbbVie$141
  • Organon$108
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$35
  • Pfizer$31
  • plus $209 from 12 others

What the payments were for

  • Food & beverage$936100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$936 in reported general payments places this provider in the 65th percentile of 1,127 physician assistant providers in Nebraska.

See all physician assistant providers in Nebraska

Medicare billing

Part B allowed, 2024
$631
Medicare patients
24
Services billed
47

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin60$51,470
OzempicSemaglutide44$47,084
EliquisApixaban43$27,883
FarxigaDapagliflozin Propanediol20$15,153
MounjaroTirzepatide11$13,214
TradjentaLinagliptin13$11,306
LantusInsulin Glargine,hum.Rec.Anlog13$4,359
SymbicortBudesonide/Formoterol Fumarate17$4,060
LevemirInsulin Detemir17$4,050
Lantus SolostarInsulin Glargine,hum.Rec.Anlog33$2,910
Desmopressin Acetate13$2,055
NovologInsulin Aspart13$1,775
Insulin Lispro Kwikpen U-100Insulin Lispro11$1,528
Atorvastatin Calcium168$1,295
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl11$1,168

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta$13$62,77673 claims
Novo NordiskOzempic, Levemir, Novolog$235$52,91074 claims
PfizerEliquis$31$27,88343 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 1,127 physician assistant providers in Nebraska.

Other physician assistant in Lincoln

See the full list for Nebraska

Where these figures come from

Is this you, or does something look wrong? →